Las Vegas, NV -- (SBWIRE) -- 12/19/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Stereotaxis Inc (NASDAQ:STXS), Syntroleum Corp (NASDAQ:SYNM), Synthetic Biologics Inc (NYSEMKT:SYN), Microsoft Corporation (NASDAQ:MSFT)
Stereotaxis Inc (NASDAQ:STXS) opened the session at $3.60, trading in a range of $3.55 - $3.96, and closed at $3.86. The stock showed a positive performance of +6.04% in the last trading session. The stock traded on a volume of 1.13 million shares and the average volume of the stock remained 655,872 shares. Stereotaxis, Inc. is a United States-based company that develops probes, devices, therapeutic and magnetic surgery delivery systems. The Company provides therapeutic delivery systems for the brain and central nervous system using magnetic stereotaxis. Its technology uses for surgical procedures and for the delivery of drugs to specific regions in the brain. Stereotaxis System is a remote-controlled magnetic instrument control and navigation platform that allows physicians to navigate catheters, guidewires and stent delivery devices through the blood vessels and chambers of the heart to treatment sites and then to effect treatment.
Will STXS Continue To Move Higher? Find Out Here
Syntroleum Corp (NASDAQ:SYNM) traded 1.11 million shares in the last business day while the average volume of the stock remained 64,974 shares. The stock showed a positive movement of +35.77% to end at $3.34. The 52 week range of the stock remained $2.39 - $7.75. Syntroleum Corporation, together with its subsidiaries, engages in the commercialization and licensing of its technologies for the production of synthetic liquid hydrocarbons.
For How Long SYNM will fight for Profitability? Read This Trend Analysis report
Synthetic Biologics Inc (NYSEMKT:SYN) reported 1.10 million shares were exchanged during the last trade, while the average volume is about 327,502 shares. The stock escalated +3.74% and finished the day at $1.11. The beta of the stock is recorded at 1.66. Synthetics Biologics, Inc., a biotechnology company, focuses on the development of biologics for the prevention and treatment of serious infectious diseases. The company?s product candidates include Trimesta, which is in Phase II clinical trial for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis.
Why Should Investors Buy SYN After The Recent Gain? Just Go Here and Find Out
Microsoft Corporation (NASDAQ:MSFT) the stock advanced +0.16% and finished the session at $36.58. Traded with volume of 63.19 million shares in the prior session and the average volume of the stock remained 43.11 million shares. Microsoft Corporation (Microsoft) develops, licenses, and supports software, services, and hardware devices worldwide. Its Windows division offers Windows operating system; Windows Services suite of applications and Web services, including Outlook.com and SkyDrive; Surface RT and Pro devices; and PC accessories.
Will MSFT Continue To Move Higher? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)